Main demographics and clinical features of patients with Behçet’s syndrome and healthy controls included in the screening and validation cohorts
| Screening cohort | Validation cohort | |||
| BS (n, % out of 16) | HC (n, % out of 18) | BS (n, % out of 30) | HC (n, % out of 30) | |
| Female sex | 7 (43.8%) | 8 (44.4%) | 17 (56.7%) | 17 (56.7%) |
| Age at enrolment, years | 42.5 (36–44.5) | 43 (36–45) | 43.5 (37–51) | 44 (36.5–52) |
| Overall disease manifestations | ||||
| Oral ulcers | 16 (100%) | – | 29 (96.6%) | – |
| Genital ulcers | 9 (56.3%) | – | 19 (63.3%) | – |
| Cutaneous | 11 (68.8%) | – | 21 (70%) | – |
| Articular | 6 (37.5%) | – | 16 (53.3%) | – |
| Ocular | 10 (62.5%) | – | 13 (43.3%) | – |
| Vascular | 6 (37.5%) | – | 14 (46.6%) | – |
| Gastrointestinal | 6 (37.5%) | – | 14 (46.6%) | – |
| Neurological | 7 (48.3 %) | – | 8 (26.6%) | – |
| Disease manifestations at enrolment | ||||
| Oral ulcers | 4 (25.0%) | – | 6 (20.0%) | – |
| Genital ulcers | 2 (12.5%) | – | 3 (10.0%) | – |
| Cutaneous | 2 (12.5%) | – | 4 (13.3%) | – |
| Articular | 2 (12.5%) | – | 1 (3.3%) | – |
| Ocular | 1 (6.3%) | – | 1 (3.3%) | – |
| Vascular | 1 (6.3%) | – | 1 (3.3%) | – |
| Gastrointestinal | 1 (6.3%) | – | 1 (3.3%) | – |
| Neurological | 1 (6.3%) | – | 0 | – |
| Active disease at enrolment | 8 (50.0%) | – | 12 (40.0%) | – |
| Immunomodulating therapy at enrolment | 13 (81.3%) | – | 29 (96.7%) | – |
Data are presented as mean±SD, median with IQR or number (n) and relative percentage when applicable. No statistically significant differences were found between groups when analysing mean age and sex ratio evaluated by Student’s t-test and χ2 test, respectively.
BDCAF, Behçet’s Disease Activity Form; BS, Behçet’s syndrome; HC, healthy controls; ICBD, International Criteria for Behçet’s Disease.